Soleno Therapeutics Inc.
Soleno Therapeutics Announces Preliminary Financial Results for Q2 2025
Summary
Soleno Therapeutics, Inc. announced preliminary financial results for the three months ended June 30, 2025. The company expects net revenue from the sales of VYKAT TM XR to be between $31.0 million and $33.0 million. Soleno had approximately $293.8 million in cash, cash equivalents, and marketable securities as of June 30, 2025. The company received approximately 646 patient start forms from around 295 unique prescribers. Soleno also had approximately $50.0 million of debt outstanding. The preliminary financial data is unaudited and subject to change.
Profitelligence Alerts
Get alerts for SLNO
Be first to know when Soleno Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Soleno Therapeutics Inc.
Soleno Therapeutics Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutics for rare diseases. Its primary focus lies on the treatment of genetic disorders that have a significant medical need, such as Prader-Willi syndrome, a complex condition that affects the musculoskeletal and endocrine systems. Soleno is committed to pioneering advancements in the pharmaceutical industry by leveraging innovative approaches to drug development. The company's lead treatment candidate, rooted in addressing metabolic and neurobehavioral abnormalities, plays a critical role within its pipeline. Soleno's research and development efforts are concentrated on improving patient outcomes through therapies that target underlying disease mechanisms. Based in Redwood City, California, Soleno Therapeutics Inc. actively collaborates with scientific communities and healthcare providers to enhance its therapeutic offerings. In the financial market, Soleno Therapeutics is notably positioned as part of the healthcare and biotechnology sectors, reflecting its significance in developing treatments that can transform patient care and address unmet medical needs in niche and complex disease areas.
Official SEC Documents
Advertisement